Telitacicept add-on therapy in refractory idiopathic inflammatory myopathy: insights from a pilot study
Telitacicept demonstrated effectiveness in treating refractory inflammatory myopathy, contributing to a significant reduction in steroid dosage among the patients. These findings highlight the potential of telitacicept as a valuable therapeutic option in the management of IIM.
Authors
- Jing Lin (ORCID: https://orcid.org/0000-0001-5901-0498)
- Mengcui Gui
- Huajie Gao
- Suqiong Ji (ORCID: https://orcid.org/0000-0002-0056-6827)
- Bitao Bu (ORCID: https://orcid.org/0000-0001-5369-7751)
- Mengge Yang (ORCID: https://orcid.org/0000-0001-7623-1022)
- Yue Li (ORCID: https://orcid.org/0000-0002-4279-2080)
Institutions
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2024-11-04
- DOI
- https://doi.org/10.1093/rheumatology/keae601
- Citations
- 5
- Primary Topic
- Inflammatory Myopathies and Dermatomyositis
- Type
- article
- Field-Weighted Citation Impact
- 1.93
Funders
- National Natural Science Foundation of China